So you now also know exactly what data Novartis were privy to as well ? That's funny ..... you just make up anything to support your narrative by the looks - Novartis partnership was based upon Remestemcel-L for COVID-19 ARDS but do now try and relate this Novartis partnership to Rexlemestrocel-L and CHF if it makes you feel better ....
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-429
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3095 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 12908 | 1 |
View Market Depth
| Last trade - 09.50am 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable